More light for Clinuvel

By Dylan Bushell-Embling
Tuesday, 23 September, 2008

Clinuvel Pharmaceuticals (ASX: CUV) has begun phase II trials of its photoprotective drug afamelanotide (CUV1657) in patients undergoing photodynamic therapy (PDT).

The trial is being conducted in a Parisian hospital and will extend to multiple health-care centres in France.

The first four of an anticipated 30 patients have been dosed, and results are expected within 12 months.

PDT is used to eradicate pre-malignant lesions of the oesophagus and as a palliative therapy in bile duct cancer. It involves administration of porfimer sodium, a photosensitiser, and a targeted light source.

One side effect is phototoxicity, with patients unable to tolerate UV light. Clinuvel anticipates that afamelanotide may offer a photoprotective effect.

Clinuvel is currently in Phase III trials of CUV1657 in erythropoietic protoporphyria (EPP), or abnormal sun sensitivity.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd